Taho Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Operating Revenue	7.78	-	1.07	6.36	12.4	36.01
Revenue	7.78	-	1.07	6.36	12.4	36.01
Revenue Growth (YoY)	-	-	-83.23%	-48.73%	-65.56%	2.68%
Cost of Revenue	2.9	-	1.14	1.3	13.54	22.36
Gross Profit	4.88	-	-0.07	5.06	-1.14	13.65
Selling, General & Admin	25.49	23.97	17.36	15.17	34.85	58.12
Research & Development	150.87	146.16	106.44	55.21	71.27	64.33
Operating Expenses	176.37	170.13	121.03	71.76	106.12	122.45
Operating Income	-171.49	-170.13	-121.1	-66.71	-107.25	-108.8
Interest Expense	-0.8	-0.9	-1.39	-0.53	-0.03	-0
Interest & Investment Income	5.06	3.02	1.3	0.52	0.63	0.31
Currency Exchange Gain (Loss)	0.86	0.34	0.27	-	-6.55	-2.15
Other Non Operating Income (Expenses)	0.42	0.24	0.24	0.43	-18.16	1.46
EBT Excluding Unusual Items	-165.97	-167.44	-120.68	-66.3	-131.36	-109.19
Gain (Loss) on Sale of Assets	-	-	-	-	-5.78	-
Pretax Income	-165.97	-167.44	-120.68	-66.3	-137.14	-109.19
Net Income	-165.97	-167.44	-120.68	-66.3	-137.14	-109.19
Net Income to Common	-165.97	-167.44	-120.68	-66.3	-137.14	-109.19
Shares Outstanding (Basic)	49	45	39	36	52	52
Shares Outstanding (Diluted)	49	45	39	36	52	52
Shares Change (YoY)	17.82%	17.18%	7.73%	-31.26%	-	-
EPS (Basic)	-3.37	-3.69	-3.12	-1.84	-2.62	-2.09
EPS (Diluted)	-3.37	-3.69	-3.12	-1.84	-2.62	-2.09
Free Cash Flow	-171.97	-165.73	-107.1	-63.61	-138.44	-103.23
Free Cash Flow Per Share	-3.49	-3.65	-2.76	-1.77	-2.65	-1.97
Gross Margin	62.67%	-	-6.75%	79.52%	-9.16%	37.90%
Operating Margin	-2204.54%	-	-11359.94%	-1049.20%	-864.87%	-302.11%
Profit Margin	-2133.50%	-	-11321.11%	-1042.75%	-1105.89%	-303.19%
Free Cash Flow Margin	-2210.67%	-	-10047.00%	-1000.49%	-1116.35%	-286.63%
EBITDA	-168.68	-168.32	-118.54	-57.77	-91.5	-92.86
EBITDA Margin	-	-	-	-	-	-257.84%
D&A For EBITDA	2.81	1.81	2.56	8.94	15.76	15.94
EBIT	-171.49	-170.13	-121.1	-66.71	-107.25	-108.8

Source: S&P Global Market Intelligence. Standard template. Financial Sources.